ArticleAdvances in therapy2014

Real-world cost-effectiveness: lower cost of treating patients to glycemic goal with liraglutide versus exenatide.

Mitch DeKoven et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.